Pfizer acquired Medivation for approximately $14 billion ($81.50 per share in cash), gaining full ownership of XTANDI (enzalutamide) for prostate cancer and the Phase III PARP inhibitor talazoparib, strengthening Pfizer's oncology portfolio.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 10yr post-close.
Key facts
AnnouncedAug 22, 2016
ClosedSep 28, 2016
Deal value$14.0B
Deal typeAcquisition/Merger
Therapeutic areaOncology
IndicationsProstate Cancer, Breast Cancer (BRCA-mutated)